Bayer’s bid to maintain its lead in the anti-vascular endothelial growth factor (VEGF) eye disease space has received a boost with a fresh approval in Europe that extends the intervals between injections for the high dose of its blockbuster Eylea.
Key Takeaways
- The European Commission has approved Eylea 8mg with an extended treatment interval of up to six months for wet AMD and DME.
The European Commission has granted a label extension for Eylea 8mg (aflibercept), or Eylea HD, with extended treatment intervals of...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?